Original Title: Clinical outcomes following “off-label” versus “established” indication of bioresorbable scaffolds for treatment of coronary artery disease in a real-world population. Reference: Tadashi Miyazaki, et al EuroIntervention 2016;11:475-478. Courtesy of Dr. Carlos Fava. Bioresorbable scaffolds (BSB) have shown their benefit in different studies, but there is little information available on “off label”...
Original Title: Drug-Coated Balloons for Complex Femoropopliteal Lesions2-Year Results of a Real-World Registry. Reference: Andrej Schmidt et al. J Am CollCardiolIntv. 2016;9(7):715-724. The superiority of drug coated balloons compared to conventional balloons in femoropopliteal lesions have been shown by randomized studies, but only in short and simple lesions. The efficacy of drug coated balloons...
Original Title: One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Lesions: Subgroup Results of the Prospective, Multicenter DEFINITIVE LE Trial. Reference: Aljoscha Rastan, et al Journal Endovascular Therapy 2015;22:839-846 Courtesy of Dr. Carlos Fava Infrapopliteal peripheral vascular disease continues to rise, especially in patients with diabetes and kidney failure, usually presenting diffuse and fairly calcified lesions. Removing...
Long lesions (≥ 15 cm), total occlusions, and in-stent restenosis represent a unique treatment challenge in peripheral vascular disease. IN.PACT Global study is a prospective, multicenter, single arm designed to evaluate the safety and efficacy of IN.PACT® ADMIRAL® drug eluting balloon for the treatment of superficial femoral and popliteal arteries in a real-world population. A...
A bioabsorbable platform implant in the context of ST segment elevation acute myocardial infarction is feasible although the subsequent cicatrization of the artery is not documented. The objective of this work was to evaluate optical coherence tomography (OCT) in patients who received everolimus-releasing bioabsorbable platform in the context of primary angioplasty. A total of 39...
Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post DES stenting. 9961 patients were randomized to continue on placebo or thienopyridine after 12 months. Thienopyridine reduces the incidence of in-stent thrombosis (0.4% vs 1.4%; p<0,001) and cardiovascular events (4.3%...
This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2: 1 (Absorb / Xience) with de novo lesions in native coronary arteries with a reference diameter between 2.25 and 3.8 mm estimated by quantitative angiography. All the patients underwent IVUS and...
Introduction: The popliteal artery is a vessel considered unfavorable for the implantation of a stent due to the forces exerted in the popliteal fossa during limb flexion, which could fracture the stent antlers and compromise the outcome of the procedure at long-term. So far, stents used in popliteal lesions have not been compared with balloon...
Original title: Hybrid Revascularization for Multivessel Coronary Artery Disease Reference: Mariuz Gassior, et al. J Am Cardiol Intv 2014;7:1277-83 According to the international guidelines, coronary artery bypass grafting (CABG) continues to be the “Gold Standard” treatment for multiple vessels diseases. However, second generation DES and the hybrid strategy may eventually change indications. This study randomized 102...
Original title: Drug-Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery. The DEBATE-SFA Randomized Trial (Drug Eluting Balloon in Peripheral Intervention for Superficial Femoral Artery). Reference: Liistro, F, el tal. J Am Coll Cardiol Intv 2013;6(12):1295-1302 The current treatment of choice in the femoropopliteal area is angioplasty, however, this procedure has a high rate of restenosis...